A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma

The purpose of this study is to investigate the efficacy and safety of neoadjuvant treatment of locally advanced esophageal squamous carcinoma with a PD-1/CTLA-4 bispecific antibody (Cadonilimab) in combination with platinum-containing chemotherapy (Paclitaxel Polymeric Micelles for Injection combined with Cisplatin). Includes pathologic complete remission rates (pCR rates) after 2-4 cycles of Cadonilimab combination chemotherapy. The objective remission rate (ORR), major pathologic remission rate (MPR), R0 resection rate and 2-year overall survival (OS) and progression-free survival (OS) rate

Trial Details

NCT ID
NCT06356688
Phase
PHASE2
Sponsor
Sun Jing
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • Paclitaxel Polymeric Micelles for Injection and Cisplatin combined with Cadonilimab
Locations (sample)
  • Nanjing, Jiangsu, China|32.06167,118.77778

Key Eligibility Criteria

  • Age ≥18 years, ≤75 years, gender is not limited;
  • Squamous esophageal cancer of thoracic segment confirmed by pathology;
  • Locally advanced patients with no distant metastasis by imaging, resectable or potentially resectable after discussion among oncology, esophageal s…
  • ECOG PS score of 0-1;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →